Cargando…

Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies

PURPOSE: To study the impact of standard-of-care hormonal therapies on metastatic prostate cancer (mPC) clinical genomic profiles in real-world practice, with a focus on homologous recombination-repair (HRR) genes. PATIENTS AND METHODS: Targeted next-generation sequencing of 1,302 patients with mPC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zurita, Amado J., Graf, Ryon P., Villacampa, Guillermo, Raskina, Kira, Sokol, Ethan, Jin, Dexter, Antonarakis, Emmanuel S., Li, Gerald, Huang, Richard S. P., Casanova-Salas, Irene, Vivancos, Ana, Carles, Joan, Ross, Jeffrey S., Schrock, Alexa B., Oxnard, Geoffrey R., Mateo, Joaquin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2022
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307307/ https://www.ncbi.nlm.nih.gov/pubmed/35820087 http://dx.doi.org/10.1200/PO.22.00195

Ejemplares similares

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023)

Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
por: Westphalen, C. Benedikt, et al.
Publicado: (2022)

Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness
por: Quintanilha, Julia C.F., et al.
Publicado: (2023)

Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas
por: Seligson, Nathan D., et al.
Publicado: (2022)

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity
por: Sokol, Ethan S., et al.
Publicado: (2020)

Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens
por: Hiemenz, Matthew C, et al.
Publicado: (2022)

Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
por: Graf, Ryon P., et al.
Publicado: (2022)

APOBEC Mutational Signatures in Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy
por: Sammons, Sarah, et al.
Publicado: (2022)

Assessment of Heterozygosity and Genome-Wide Analysis of Heterozygosity Regions in Two Duroc Pig Populations
por: Ruan, Donglin, et al.
Publicado: (2022)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes with Targeted Therapies in Real-World Cases of Colorectal Cancer
por: Quintanilha, Julia C F, et al.
Publicado: (2023)

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature
por: Batalini, Felipe, et al.
Publicado: (2023)

Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors
por: Lee, Jessica K., et al.
Publicado: (2022)

Inferring Heterozygosity from Ancient and Low Coverage Genomes
por: Kousathanas, Athanasios, et al.
Publicado: (2017)

Genomic loss of heterozygosity and survival in the REAL3 trial
por: Smyth, Elizabeth C., et al.
Publicado: (2018)

Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma
por: Bustamante, Bethany, et al.
Publicado: (2021)

The Association Between Genomic Heterozygosity and Carcass Merit in Cattle
por: Kenny, David, et al.
Publicado: (2022)

Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2022)

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC
por: Schwartzberg, Lee S., et al.
Publicado: (2022)

Clonal polymorphism and high heterozygosity in the celibate genome of the Amazon molly
por: Warren, Wesley C., et al.
Publicado: (2018)

Genome-scale patterns in the loss of heterozygosity incidence in Saccharomyces cerevisiae
por: Tutaj, Hanna, et al.
Publicado: (2022)

Genome plasticity driven by aneuploidy and loss of heterozygosity in Trypanosoma cruzi
por: Cruz-Saavedra, Lissa, et al.
Publicado: (2022)

Transposable elements maintain genome-wide heterozygosity in inbred populations
por: De Kort, Hanne, et al.
Publicado: (2022)

Facial attractiveness is only weakly linked to genome–wide heterozygosity
por: Fieder, Martin, et al.
Publicado: (2023)

A practical assembly guideline for genomes with various levels of heterozygosity
por: Mochizuki, Takako, et al.
Publicado: (2023)

Genomic landscape of 891 RET fusions detected across diverse solid tumor types
por: Parimi, Vamsi, et al.
Publicado: (2023)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

Loss of heterozygosity preferentially occurs in early replicating regions in cancer genomes
por: Pedersen, Brent S., et al.
Publicado: (2013)

Genomic Analysis Reveals Specific Patterns of Homozygosity and Heterozygosity in Inbred Pigs
por: Wang, Ligang, et al.
Publicado: (2019)

Comparison Between Flat and Round Peaches, Genomic Evidences of Heterozygosity Events
por: Tan, Qiuping, et al.
Publicado: (2019)

Corrigendum: Genome plasticity driven by aneuploidy and loss of heterozygosity in Trypanosoma cruzi
por: Cruz-Saavedra, Lissa, et al.
Publicado: (2022)

Genomic heterozygosity is associated with parasite abundance, but the effects are not mediated by host condition
por: Budischak, Sarah A., et al.
Publicado: (2022)

Evolution of loss of heterozygosity patterns in hybrid genomes of Candida yeast pathogens
por: Mixão, Verónica, et al.
Publicado: (2023)

Cosegregation of recombinant chromatids maintains genome-wide heterozygosity in an asexual nematode
por: Blanc, Caroline, et al.
Publicado: (2023)

The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer
por: Gitlitz, Barbara J., et al.
Publicado: (2021)

PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers
por: Sokol, Ethan S., et al.
Publicado: (2022)

Genomic alterations in nasopharyngeal carcinoma: loss of heterozygosity and Epstein-Barr virus infection.
por: Mutirangura, A., et al.
Publicado: (1997)

Developmental Stability Covaries with Genome-Wide and Single-Locus Heterozygosity in House Sparrows
por: Vangestel, Carl, et al.
Publicado: (2011)

High genome heterozygosity and endemic genetic recombination in the wheat stripe rust fungus
por: Zheng, Wenming, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_85uc597qhfu97v2lbct78p60gr